Reversal of P-glycoprotein mediated vincristine resistance of L1210/VCR cells by analogues of pentoxifylline: A QSAR study

European Journal of Pharmaceutical Sciences

Volumn 21, Issue 2-3, 2004, Pages 283-293

  Kupsáková, Ivana ^a   Rybár, Alfons ^a   Dočolomanský, Peter ^b   Drobná, Zuzana ^a   Stein, Ulrike ^c   Walther, Wolfgang ^c   Barančík, Miroslav ^a   Breier, Albert ^b  

^a INSTITUTE OF CHEMISTRY   (Slovakia)

^b INSTITUTE OF MOLECULAR PHYSIOLOGY AND GENETICS   (Slovakia)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

L1210 cell line; Multidrug resistance; P glycoprotein; Pentoxifylline analogues; Structure activity relationship; Vincristine; Xanthines

Indexed keywords

CAFFEINE; DACTINOMYCIN; GLYCOPROTEIN P; ISOBUTYLMETHYLXANTHINE; METHYLXANTHINE DERIVATIVE; MITOMYCIN C; OCTANOL; PENTOXIFYLLINE; PROPENTOFYLLINE; THEOPHYLLINE; VINCRISTINE; WATER;

ANIMAL CELL; ARTICLE; CORRELATION ANALYSIS; CRYSTAL; DENSITY; DRUG EFFICACY; DRUG STRUCTURE; IC 50; LEUKEMIA L 1210; MATHEMATICAL COMPUTING; MOLECULAR WEIGHT; MOUSE; MULTIDRUG RESISTANCE; MULTIPLE REGRESSION; NONHUMAN; PARTITION COEFFICIENT; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

EID: 17444434686     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2003.10.019     Document Type: Article

References (41)

1. Barančík M., Boháčová V., Kvačkajová J., Hudecová S., Križanová O., Breier A. SB203580, a specific inhibitor of p38-MAPK pathway, is a new reversal agent of P-glycoprotein-mediated multidrug resistance. Eur. J. Pharm. Sci. 14:2001;29-36.
2. Boháčová V., Kvačkajová J., Barančík M., Drobná Z., Breier A. Glutathione S-transferase does not play a role in multidrug resistance of L1210/VCR cell line. Physiol. Res. 49:2000;447-453.
3. Bolger, M.B., 2003. Therapeutics I, http://www.usc.edu/hsc/pharmacy/ curriculum/l2/Phar414/PhysicoChemicalProp02.PDF .
4. Breier A., Barančík M., Štefanková Z., Uhrík B., Tribulová N. Effect of pentoxifylline on P-glycoprotein mediated vincristine resistance of L1210 mouse leukemic cell line. Neoplasma. 41:1994a;297-303.
5. 3H]-vincristine accumulation by L1210 mouse leukemic cells. Effect of P-glycoprotein overexpression. Gen. Physiol. Biophys. 13:1994b;287-298.
6. Breier, A., Drobná, Z., Boháčová, V., Barančík, M., 1998. Resistance of L1210 mouse leukemic cell line characterized by overexpression of ATP dependent drug transporter to several drugs. Chem. Pap. - Chem. Zvesti 52 Sp. Iss., 418-419.
7. Breier A., Drobná Z., Dočolomanský P., Barančík M. Cytotoxic activity of several unrelated drugs on L1210 mouse leukemic cell sublines with P-glycoprotein (PGP) mediated multidrug resistance (MDR) phenotype. A QSAR study. Neoplasma. 47:2000;100-106.
8. Cavallaro R.A., Filocamo L., Galuppi A., Galione A., Brufani M., Genazzani A.A. Potentiation of cADPR-induced Ca(2+)-release by methylxanthine analogues. J. Med. Chem. 42:1999;2527-2534.
9. Chitnis M.P., Viladkar A.B., Juvekar A.S. Inhibition of DNA biosynthesis by vincristine and pentoxifylline in murine p388 leukemia-cells resistant to doxorubicin. Neoplasma. 37:1990;619-626.
10. Daly J.W. Alkylxanthines as research tools. J. Autonom. Nerv. Syst. 81:2000;44-52.
11. Drobná Z., Stein U., Walther W., Barančík M., Breier A. Pentoxifylline influences drug transport activity of P-glycoprotein and decreases mdr1 gene expression in multidrug resistant mouse leukemic L1210/VCR cells. Gen. Physiol. Biophys. 21:2002;103-109.
12. Gottesman M.M., Pastan I. Biochemistry of multidrug-resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62:1993;385-427.
13. Hatheway G.J., Hansch C., Kim K.H., Milstein S.R., Schmidt C.L., Smith R.N., Quinn F.R. Antitumor 1-(X-aryl)-3,3-dialkyltriazenes. 1. Quantitative structure-activity relationships vs. L1210 leukemia in mice. J. Med. Chem. 21:1978;563-574.
14. Juliano R.L., Ling V. Surface glycoprotein modulating drug permeability in Chinese-hamster ovary cell mutants. Biochim. Biophys. Acta. 455:1976;152-162.
15. Kaplan J.M., Herzyk D.J., Ruggieri E.V., Bartus J.O., Esser K.M., Bugelski P.J. Effect of TNF-alpha production inhibitors brl-61063 and pentoxifylline on the response of rats to poly-I-C. Toxicology. 95:1995;187-196.
16. Kišucká J., Barančík M., Boháč ová V., Breier A. Reversal effect of specific inhibitors of extracellular-signal regulated protein kinase pathway on P-glycoprotein mediated vincristine resistance of L1210 cells. Gen. Physiol. Biophys. 20:2001;439-444.
17. Klotz K.N. Adenosine receptors and their ligands. Naunyn Schmiedebergs Arch. Pharmacol. 362:2000;382-391.
18. Krishna R., Mayer L.D. Multidrug resistance (MDR) in cancer - mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci. 11:2000;265-283.
19. Kupsáková I., Dočolomanský P., Rybár A., Barančík M., Breier A. Carbonyl group of aliphatic side chain of pentoxifylline does not play role for P-glycoprotein antagonizing effect of pentoxifylline. Gen. Physiol. Biophys. 21:2002;471-478.
20. Kvačkajová-Kišucká J., Barančí k M., Breier A. Drug transporters and their role in multidrug resistance of neoplastic cells. Gen. Physiol. Biophys. 20:2001;215-237.
21. 2+ release channel. Pharmacology. 54:1997;135-143.
22. Marucci L., Varticovski L., Arias I.M. Effect of a xanthine analog on human hepatocellular carcinoma cells (Alexander) in culture and in xenografts in SCID mice. Hepatology. 26:1997;1195-1202.
23. Miyamoto K., Sakai R., Kurita M., Ohmae S., Sanae F., Sawanishi H.et al. Effects of alkyl substituents of xanthine on phosphodiesterase isoenzymes. Biol. Pharm. Bull. 18:1995;431-434.
24. Ojima I., Bounaud P.Y., Oderda C.F. Recent strategies for the treatment of multi-drug resistance in cancer cells. Expert Opin. Ther. Pat. 8:1998;1587-1598.
25. Österberg T., Norinder U. Prediction of drug transport processes using simple parameters and PLS statistics. The use of ACD/log. P and ACD/ChemSketch descriptors Eur. J. Pharm. Sci. 12:2001;327-337.
26. Poleková L., Barančík M., Mrázová T., Pirker R., Wallner J., Sulová Z.et al. Adaptation of mouse leukemia-cells L1210 to vincristine - evidence for expression of p-glycoprotein. Neoplasma. 39:1992;73-77.
27. Rauko P., Sedlák J., Duraj J., Szekeres M.F., Novotný L. Pentoxifylline stimulates drug-induced apoptosis in leukemic cells. Neoplasma. 45:1998;296-300.
28. Rybár A., Turčáni P., Alfoldi J. 1-(Oxoalkyl)-3,7,8-trialkyl-3,7-dihydro-1H-purine-2,6-diones. Collect. Czech. Chem. C. 58:1993;1169-1179.
29. Rybár A., Turčáni P., Alfoldi J. 8-Substituted 7-(oxoalkyl)theophyllines. Chem. Pap. - Chem. Zvesti. 48:1994;47-50.
30. Sadzuka Y., Egawa Y., Sawanishi H., Miyamoto K., Sonobe T. Effects of xanthine derivatives on the influx and efflux of doxorubicin in P388 and DOX-resistant P388 leukemia cells. Toxicol. Lett. 135:2002;137-144.
31. Sadzuka Y., Sugiyama T., Sawanishi H., Miyamoto K. Enhanced efficacy of 1-methyl-3-propyl-7-butylxanthine on the antitumor activity of doxorubicin against doxorubicin-resistant P388 leukemia. Cancer. Lett. 138:1999;5-11.
32. Semmler J., Gebert U., Eisenhut T., Moeller J., Schonharting M.M., Allera A.et al. Xanthine derivatives - comparison between suppression of tumor-necrosis-factor-alpha production and inhibition of camp phosphodiesterase activity. Immunology. 78:1993;520-525.
33. Strappaghetti G., Corsano S., Barbaro R., Giannaccini G., Betti L. Structure-activity relationships in a series of 8-substituted xanthines as A1-adenosine receptor antagonists. Bioorg. Med. Chem. 9:2001;575-583.
34. Štefanková Z., Barančík M., Breier A. Overcoming of P-glycoprotein mediated vincristine resistance of L1210/VCR mouse leukemic cells could be induced by pentoxifylline but not by theophylline and caffeine. Neoplasma. 43:1996;11-15.
35. Stein U., Walther W., Shoemaker R.H. Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells. J. Natl. Cancer Inst. 88:1996;1383-1392.
36. 2+ antagonists on multidrug resistance, MDR1-mediated transport and MDR1 mRNA expression. Eur. J. Pharm. Sci. 16:2002;159-165.
37. Van de Waterbeemd H., Carter E., Grassy G., Kubinyi H., Martin Y.C., Tute M.S.et al. Glossary of terms used in computational drug design. Pure Appl. Chem. 69:1997;1137-1152.
38. Van Furth A.M., Seijmonsbergen E.M., Langermans J.A.M., Van Der Meide P.H., Van Furth R. Effect of xanthine derivates and dexamethasone on streptococcus pneumoniae-stimulated production of tumor necrosis factor alpha, interleukin-1b (il-1b), and il-10 by human leukocytes. Clin. Diagn. Lab. Immunol. 2:1995;689-692.
39. Viladkar A.B., Chitnis M.P. In-vitro effects of pentoxifylline and doxorubicin on cell-survival and DNA-damage in sensitive and MDR-p388 leukemia-cells. Cancer Biother. 9:1994;143-151.
40. Walther W., Stein U., Eder C. RNA analysis using miniprep RNA in RT-PCR. Biotechniques. 17:1994;674-675.
41. Wu L., Smythe A.M., Stinson S.F., Mullendore L.A., Monks A., Scudiero D.A., Paull K.D., Koutsoukos A.D., Rubinstein L.V., Boyd M.R. Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening. Cancer Res. 52:1992;3029-3034.